VIDEO: Switching to bimekizumab improved psoriasis outcomes
Click Here to Manage Email Alerts
Switching to bimekizumab resulted in better outcomes among certain patients with psoriasis who did not respond as well to adalimumab, according to results presented at AAD VMX 2021.
In this video, April Armstrong, MD, MPH, of the Keck School of Medicine at the University of Southern California, Los Angeles, discussed how 61% of patients who were randomly assigned to adalimumab (Humira, AbbVie) at the beginning of the study achieved a Psoriasis Area and Severity Index score of at least 90 after switching to bimekizumab (Cimzia, UCB).
These findings are encouraging, she noted, and highlight the availability of more treatment options for patients with psoriasis.
“Our toolbox for biologics has increased and the advent of newer biologics are really pushing the envelope with regards to how efficacious our biologics can be for patients with moderate to severe plaque psoriasis. It also can inform us with regards to how we can switch between one biologic and another,” Armstrong said.